Emergent BioSolutions Inc. — Director's Dealing 2020

Sep 12, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2020-09-09

Reporting Person: El-Hibri Fuad (Director, Chairman, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-09-09	Common Stock	S	20000	$102.80	Disposed	1209523	Direct
2020-09-10	Common Stock	S	20000	$102.66	Disposed	1189523	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2140463	Indirect
Common Stock	1524155	Indirect

Footnotes

F1: The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act").

F2: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.88 to $105.10.

F3: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.72 to $104.06.

F4: The decrease in the number of shares of the Issuer's common stock held by Invervac, L.L.C. ("Intervac") does not reflect a sale of such shares by Intervac. On August 25, 2020 Intervac completed an internal restructuring pursuant to which Intervac redeemed all of the membership interests in Intervac held by members that were not controlled or managed, directly or indirectly, by Mr. El-Hibri or Mrs. El-Hibri. In consideration for such redemption, Intervac effected a pro-rata distribution of an aggregate of 2,177,121 shares of the Issuer's common stock to such non-affiliated members. After giving effect to the pro-rata distribution, Intervac is the direct owner of 2,140,463 shares of the Issuer's common stock and either Mr. El-Hibri or Mrs. El-Hibri serve as the trustee of each of the remaining members of Intervac.

F5: (continued from footnote 4) Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein, which such pecuniary interest did not change as a result of the above described transaction.

F6: Mr. El-Hibri, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C, which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.